Trastuzumab Active Not Recruiting Phase 3 Trials for Metastatic Breast Cancer (MBC) Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT00567190A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer
NCT01989676A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)
NCT01526369A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer
NCT01084876Demonstrate Efficacy and Safety of Metastatic Breast Cancer